p.trevino

TL2 · Ilorin

Contributes reviews on supplier material. Based in Ilorin.

Joined 12 May 2025 · last posted 13d

80Posts here

1Topics

1Solutions

1.3kLikes received

853Likes given

21Badges

194Days visited

3.5kPosts read

Recent activity

Full stream

Journal club: what we got wrong in an earlier session Replied, post #86 · Evidence › Journal club · 15 Jul 2026 · 29 likes The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.
How shortages have affected compounding permissions Replied, post #13 · Access › Shortages · 3 Jul 2026 · 1 like Two sentences on shortages and then I will stop, because the rest is speculation and the thread is better without mine. What is documented is narrow. What is inferred…
Immortal time bias in a claims-database study — one year on Replied, post #5 · marked as the solution · Evidence › Study critique · 2 Jul 2026 · 20 likes A run-in period that excludes non-responders before randomisation changes what the trial is estimating. It is legitimate design and it must be stated in any summary.
Prescription requirements and telehealth models — a second dataset Replied, post #88 · Sourcing › Regulatory · 2 Jul 2026 · 0 likes The version of Prescription requirements and telehealth models that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had…
What a certificate commits its issuer to — one year on Replied, post #95 · Analytics › COA interpretation · 24 Jun 2026 · 1 like Post #93 describes the usual case. This is about the unusual one. Peptide content and chromatographic purity are separate determinations and a certificate that reports…
Naming conventions for research peptides and the confusion they cause Replied, post #12 · Compounds › Other compounds · 7 Jun 2026 · 11 likes Post #9 is the version of this I will quote in future. One addition. Adding the boring version of naming conventions for research peptides, because the interesting…
Reading a trial's population section before its results Replied, post #88 · Evidence › Trials · 4 Jun 2026 · 2 likes Funding and trial conduct should be stated and are a weak predictor of anything on their own. Design quality is the stronger signal and it is checkable. Correct me on…
An appeal that succeeded, with the letter structure — the long version Replied, post #48 · Access › Insurance & coverage · 3 Jun 2026 · 19 likes On appeal the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.
Micro-titration: a disputed topic, argued properly Replied, post #82 · Practice › Dosing & titration · 31 May 2026 · 16 likes Post #79 is right about the mechanism and I think understates the practical bit. Reframing micro-titration slightly, because I think the disagreement is about the…
Reading a trial's population section before its results Replied, post #63 · Evidence › Trials · 28 May 2026 · 3 likes Acknowledging rather than arguing. The reasoning holds as far as I can follow it.
Revisiting: Primary endpoint hierarchies and why order matters Replied, post #26 · Evidence › Trials · 12 May 2026 · 0 likes Absolute numbers, not just relative: a 30% relative reduction tells you the ratio but not the practical magnitude. The event rate in each arm and the difference between…
Coming back to: Solubility limits and what a cloudy solution is telling you Replied, post #22 · Pharmacology › Formulation chemistry · 11 May 2026 · 0 likes Post #18 put the caveat in the right place and I want to underline it. Isotonicity: an isotonic solution has the same osmotic pressure as blood. Non-isotonic solutions…